Quotient Sciences expands service portfolio with Arcinova acquisition

The acquisition will extend the 12-month drug development timeline savings already delivered by Quotient’s flagship platform Translational Pharmaceutics

Quotient said the acquisition will enable it to integrate drug substance, drug product and clinical testing capabilities all under one organization — extending the 12-month drug development timeline savings already delivered by Quotient’s flagship platform Translational Pharmaceutics.

Arcinova's 160,000-sq. ft2 (15,000 m2) single site in Alnwick, UK, has been providing integrated services from candidate to Phase II for around 40 years.

In October, Arcinova installed an R1000 robotic capsule filler, including patented micro-dosing technology to support the handling of challenging powders with particularly poor flow properties.

The CDMO also purchased the Sciex 6600 T-TOF system equipped with an Exion LC front end and Sciex BioTool software to enable the company to rapidly characterise the intact masses of large biological molecules, and at the same time accurately quantify them in difficult matrices.

According to Quotient Sciences' CEO, Mark Egerton, both businesses share a similar culture and provide services to "accelerate molecules from candidate selection through development and on to commercial launch".

As part of the deal, Arcinova’s minority equity partner, BGF, will exit the business, having backed its growth since 2018.